2023年ESMO乳腺癌治疗最新进展

doi:10.19401/j.cnki.1007-3639.2023.11.002

中国癌症杂志 ›› 2023, Vol. 33 ›› Issue (11): 981-988.doi: 10.19401/j.cnki.1007-3639.2023.11.002

2023年ESMO乳腺癌治疗最新进展

周腾¹^,²^,³(), 张剑¹^,²^,³()

复旦大学附属肿瘤医院大内科，复旦大学附属肿瘤医院Ⅰ期临床试验病房，复旦大学上海医学院肿瘤学系，上海 200032

收稿日期:2023-11-10 修回日期:2023-11-17 出版日期:2023-11-30 发布日期:2023-12-14
通信作者: 张剑（ORCID: 0000-0002-7890-4187），博士，主任医师，复旦大学附属肿瘤医院Ⅰ期临床试验病房副主任。
作者简介:周腾（ORCID: 0009-0004-8350-864X），硕士在读。
张剑，复旦大学附属肿瘤医院大内科主任医师。医疗特长：常见肿瘤（实体瘤）的诊断和治疗，乳腺癌和泌尿系统肿瘤的化疗/靶向治疗，抗肿瘤新药临床研究。担任上海市抗癌协会肿瘤药物临床研究专业委员会候任主任委员、中国抗癌协会乳腺癌专业委员会常委、中国抗癌协会乳腺癌专业委员会青委会副召集人、国家抗肿瘤药物临床应用监测青年专家委员会副主任委员。以第一作者、共同第一作者和通信作者在SCI收录期刊上发表论文70余篇。主持国家自然科学基金面上项目、上海市自然科学基金等10余项课题。曾荣获“全国首届妇幼健康科技奖科技成果奖”一等奖两次、“上海医学科技奖”一等奖、“江苏省科学技术奖”一等奖、“上海市抗癌协会科技奖”一等奖等。

The latest progress of breast cancer treatment at 2023 ESMO

ZHOU Teng¹^,²^,³(), ZHANG Jian¹^,²^,³()

Department of Medical Oncology, Fudan University Shanghai Cancer Center; Phase Ⅰ Clinical Trial Center, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China

Received:2023-11-10 Revised:2023-11-17 Published:2023-11-30 Online:2023-12-14

摘要/Abstract

摘要：

在2023年欧洲肿瘤内科学会（European Society of Medical Oncology，ESMO）年会上，多项乳腺癌领域的最新研究成果公布。在早期乳腺癌方面，免疫检查点抑制剂不仅持续证实了在三阴性乳腺癌新辅助治疗中的价值（KEYNOTE-522和NeoTRIP），也显示出其在激素受体+/人表皮生长因子受体2（human epidermal growth factor receptor 2，HER2）-乳腺癌新辅助治疗中的潜在获益（KEYNOTE-756和CheckMate 7FL）；细胞周期蛋白依赖性激酶4/6（cyclin-dependent kinase 4/6，CDK4/6）抑制剂（如monarchE和NATALEE研究所示）也巩固了在激素受体+/HER2-乳腺癌辅助强化治疗中的重要地位。在晚期乳腺癌治疗方面，新的内分泌治疗选择及抗体药物偶联物（如T-DXd和Dato-DXd）为激素受体+/HER2-患者带来治疗新机遇；汇总分析提示T-DXd对HER2+乳腺癌脑转移疗效表现突出；Dato-DXd联合免疫治疗、新靶点抗体药物偶联物HS-20089分别在一线和后线三阴性乳腺癌治疗中产生可喜效果。

关键词: 乳腺癌治疗, 免疫检查点抑制剂, 细胞周期蛋白依赖性激酶4/6抑制剂, 抗体药物偶联物

Abstract:

At 2023 Annual Meeting of European Society of Medical Oncology (ESMO), Several latest research achievements in the field of breast cancer were announced. For early-stage breast cancer, immune checkpoint inhibitor has not only continued to prove their value in the neoadjuvant treatment of triple-negative breast cancer (KEYNOTE-522 and NeoTRIP), but also shown their potential benefit in the neoadjuvant therapy of hormone receptor+/human epidermal growth factor receptor 2 (HER2)- breast cancer (KEYNOTE-756 and CheckMate 7FL). Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors (as shown in the MONARCHE and NATALEE studies) have also solidified an important position in the adjuvant intensive treatment of hormone receptor+/HER2- breast cancer. In advanced breast cancer treatment, new endocrine therapy options and antibody-drug conjugate (T-DXd and Dato-DXd) have opened up new therapeutic opportunities for hormone receptor+/HER2- patients. Pooled analyses suggest that T-DXd has demonstrated outstanding efficacy in brain metastases of HER2+ breast cancer. Dato-DXd in combination with immunization and the new targeted antibody-drug conjugate HS-20089 produced promising efficacy in first-line treatment of and post-line triple-negative breast cancer, respectively.

Key words: Breast cancer treatment, Immune checkpoint inhibitor, Cyclin-dependent kinase 4/6 inhibitors, Antibody-drug conjugate

中图分类号:

R737.9

周腾, 张剑. 2023年ESMO乳腺癌治疗最新进展[J]. 中国癌症杂志, 2023, 33(11): 981-988.

ZHOU Teng, ZHANG Jian. The latest progress of breast cancer treatment at 2023 ESMO[J]. China Oncology, 2023, 33(11): 981-988.

参考文献 26

[1]	CARDOSO F. LBA21 KEYNOTE-756: phase Ⅲ study of neoadjuvant pembrolizumab (pembro) or placebo (pbo)+chemotherapy (chemo), followed by adjuvant pembro or pbo+endocrine therapy (ET) for early-stage high-risk ER+/HER2- breast cancer[J]. Ann Oncol, 2023, 34: S1260-S1261. doi: 10.1016/j.annonc.2023.10.011
[2]	LOI S, CURIGLIANO G, SALGADO R F, et al. LBA20 A randomized, double-blind trial of nivolumab (NIVO) vs placebo (PBO) with neoadjuvant chemotherapy (NACT) followed by adjuvant endocrine therapy (ET)±NIVO in patients (pts) with high-risk, ER+ HER2- primary breast cancer (BC)[J]. Ann Oncol, 2023, 34: S1259-S1260. doi: 10.1016/j.annonc.2023.10.010
[3]	O’SHAUGHNESSY J, JOHNSTON S R D, HARBECK N, et al. Primary outcome analysis of invasive disease-free survival for monarchE: abemaciclib combined with adjuvant endocrine therapy for high-risk early breast cancer[C]. 2020 San Antonio Breast Cancer Symposium, 2020: Abstract GS1- 01.
[4]	JOHNSTON S, TOI M, O’SHAUGHNESSY J, et al. Abemaciclib plus endocrine therapy for HR+, HER2-, node-positive, high-risk early breast cancer: results from a pre-planned monarchE overall survival interim analysis, including 4-year efficacy outcomes[C]. SABCS, 2022.
[5]	HARBECK N. LBA17 Adjuvant abemaciclib plus endocrine therapy for HR+, HER2-, high-risk early breast cancer: results from a preplanned monarchE overall survival interim analysis, including 5-year efficacy outcomes[J]. Ann Oncol, 2023, 34: S1256. doi: 10.1016/j.annonc.2023.10.007
[6]	SLAMON D J, STROYAKOVSKIY D, YARDLEY D A, et al. Ribociclib and endocrine therapy as adjuvant treatment in patients with HR+/HER2- early breast cancer: primary results from the phase Ⅲ NATALEE trial[J]. J Clin Oncol, 2023, 41(17_suppl): LBA500. doi: 10.1200/JCO.2023.41.17_suppl.LBA500
[7]	BARDIA A, HORTOBAGYI G N, LIPATOV O, et al. LBA23 Invasive disease-free survival (iDFS) across key subgroups from the phase Ⅲ NATALEE study of ribociclib (RIB)+a nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+/HER2- early breast cancer (EBC)[J]. Ann Oncol, 2023, 34: S1261-S1262.
[8]	KOI Y, TAJIRI W, KAWASAKI J, et al. The impact of low HER2 expression on clinical significances and outcomes in patients with HER2-negative early breast cancer[J]. Ann Oncol, 2023, 34: S278-S324.
[9]	SCHMID P, CORTÉS J, DENT R A, et al. LBA18 Pembrolizumab or placebo plus chemotherapy followed by pembrolizumab or placebo for early-stage TNBC: updated EFS results from the phase Ⅲ KEYNOTE-522 study[J]. Ann Oncol, 2023, 34: S1257. doi: 10.1016/j.annonc.2023.10.008
[10]	GIANNI L, HUANG C S, EGLE D, et al. Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple negative, early high risk and locally advanced breast cancer. NeoTRIP Michelangelo randomized study[J]. Ann Oncol, 2022: S0923- 7534(22)00113-2.
[11]	GIANNI L. Event-free survival (EFS) analysis of neoadjuvant taxane/carboplatin with or without atezolizumab followed by an adjuvant anthracycline regimen in high-risk triple negative breast cancer (TNBC): NeoTRIP Michelangelo randomized study[J]. Ann Oncol, 2023, 34: S1258-S1259. doi: 10.1016/j.annonc.2023.10.009
[12]	MITTENDORF E A, ZHANG H, BARRIOS C H, et al. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial[J]. Lancet, 2020, 396(10257): 1090-1100. doi: 10.1016/S0140-6736(20)31953-X pmid: 32966830
[13]	ROBERTSON J. Final overall survival analysis for fulvestrant vs anastrozole in endocrine therapy (ET)-naïve, hormone receptor-positive (HR+) advanced breast cancer (FALCON)[J]. Ann Oncol, 2023, 34: S339-S340. doi: 10.1016/j.annonc.2023.09.561
[14]	TARANTINO P, HAMILTON E, TOLANEY S M, et al. HER2-low breast cancer: pathological and clinical landscape[J]. J Clin Oncol, 2020, 38(17): 1951-1962. doi: 10.1200/JCO.19.02488 pmid: 32330069
[15]	MODI S, JACOT W, YAMASHITA T, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer[J]. N Engl J Med, 2022, 387(1): 9-20. doi: 10.1056/NEJMoa2203690
[16]	MODI S. Trastuzumab deruxtecan (T-DXd) versus treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): updated survival results of the randomized, phase Ⅲ DESTINY-Breast04 study[J]. Ann Oncol, 2023, 34: S334-S335. doi: 10.1016/j.annonc.2023.09.553
[17]	BARDIA A. Datopotamab deruxtecan (Dato-DXd) vs chemotherapy in previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer (BC): primary results from the randomised phase Ⅲ TROPION-Breast01 trial[J]. Ann Oncol, 2023, 34: S1264-S1265. doi: 10.1016/j.annonc.2023.10.015
[18]	OUYANG Q, YIN Y, SONG L, et al. SKB264 (MK-2870) in previously treated hormone receptor-positive (HR+)/HER2-negative metastatic breast cancer (mBC): results from a phase Ⅰ/Ⅱ, single-arm, basket trial[J]. Ann Oncol, 2023, 34: S337.
[19]	CURIGLIANO G, CASTELO-BRANCO L, GENNARI A, et al. ESMO metastatic breast cancer living guidelines, v1.1 May 2023[J]. Ann Oncol, 2021, 32(12): 1475-1495. doi: 10.1016/j.annonc.2021.09.019
[20]	MÜLLER V, BARTSCH R, LIN N U, et al. Epidemiology, clinical outcomes, and unmet needs of patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases: a systematic literature review[J]. Cancer Treat Rev, 2023, 115: 102527. doi: 10.1016/j.ctrv.2023.102527
[21]	HURVITZ S A. A pooled analysis of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (mBC) with brain metastases (BMs) from DESTINY-Breast (DB)-01, -02, and-03[J]. Ann Oncol, 2023, 34: S335-S336. doi: 10.1016/j.annonc.2023.09.554
[22]	AFTIMOS P G, TURNER N, O’SHAUGHNESSY J, et al. Trastuzumab duocarmazine versus physician’s choice therapy in pre-treated HER2-positive metastatic breast cancer: final results of the phase Ⅲ TULIP trial[J]. Ann Oncol, 2023, 34: S340-S341.
[23]	ZHANG J. A multicenter, open-label, dose escalation and expansion study of DP303c in patients with HER2-positive pre-treated advanced solid tumors[J]. Ann Oncol, 2023, 34: S340.
[24]	FUENTES-ANTRÁS J, GENTA S, VIJENTHIRA A, et al. Antibody-drug conjugates: in search of partners of choice[J]. Trends Cancer, 2023, 9(4): 339-354. doi: 10.1016/j.trecan.2023.01.003
[25]	SCHMID P. Datopotamab deruxtecan (Dato-DXd)+durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): updated results from BEGONIA, a phase Ⅰb/Ⅱ study[J]. Ann Oncol, 2023, 34: S337.
[26]	WU J, ZHANG J, LI H, et al. First-in-human/phase Ⅰ trial of HS-20089, a B7-H4 ADC, in patients with advanced solid tumors[J]. Ann Oncol, 2023, 34: S336.

2023年ESMO乳腺癌治疗最新进展

The latest progress of breast cancer treatment at 2023 ESMO

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 26

相关文章 15

编辑推荐

Metrics

本文评价

[1]	康殷楠, 陈顺, 解有成, 郑英, 何昱静, 李初谊, 于晓辉. 抗体药物偶联物在HER2阳性晚期胃癌中的应用进展和展望[J]. 中国癌症杂志, 2023, 33(8): 790-800.
[2]	张皓婷, 郑静, 傅梦姣, 周建英. 免疫治疗肺癌诱发甲状腺功能异常的研究进展[J]. 中国癌症杂志, 2023, 33(7): 701-706.
[3]	左学良, 陈志强, 董润雨, 王智雄, 蔡娟. 联合检测LDHA和PD-L1在晚期胃癌PD-1抑制剂疗效预测及预后评估中的价值[J]. 中国癌症杂志, 2023, 33(5): 460-468.
[4]	陈君瑶, 张文涛, 刘巧, 聂建云. 老年三阴性乳腺癌患者的临床困境和系统治疗策略[J]. 中国癌症杂志, 2023, 33(5): 506-516.
[5]	曾铖, 张剑. 2022年度ADC在胰腺癌领域的研究新进展及展望[J]. 中国癌症杂志, 2023, 33(3): 235-240.
[6]	夏玲芳, 朱俊, 吴小华. 2023年ESMO妇科肿瘤治疗最新进展及展望[J]. 中国癌症杂志, 2023, 33(11): 969-980.
[7]	中国抗癌协会肿瘤内分泌专业委员会. 妇科恶性肿瘤免疫治疗中国专家共识（2023年版）[J]. 中国癌症杂志, 2023, 33(10): 954-967.
[8]	许宇辰, 程蕾蕾, 王妍, 林瑾仪, 陈佳慧, 陈怡帆, 周宇红, 刘天舒, 葛均波. sST2在免疫检查点抑制剂相关不良反应风险预测中的价值[J]. 中国癌症杂志, 2022, 32(8): 712-718.
[9]	陈怡帆, 程蕾蕾, 沈毅辉, 张卉, 汪雪君, 许宇辰, 葛均波. 程序性死亡[蛋白]-1抑制剂诱导小鼠心肌炎模型的建立[J]. 中国癌症杂志, 2022, 32(7): 606-613.
[10]	吴建辉, 储香玲, 王李强, 林心情, 谢晓鸿, 谢梦青, 赵静, 邓海怡, 杨伊霖, 邱桂焕, 周茂林, 孙霓, 李茹, 陈萤, 邓佳茜, 曾晨, 潘柏林, 秦茵茵, 刘明, 苏春霞, 周承志. 中国肺癌患者真实世界免疫检查点抑制剂相关性肺炎的流行病学分析[J]. 中国癌症杂志, 2022, 32(6): 469-477.
[11]	苏春霞, 周彩存. 晚期非小细胞肺癌免疫治疗现状及未来方向[J]. 中国癌症杂志, 2022, 32(6): 478-486.
[12]	江健韵, 应红梅. BRAF V600突变阳性的晚期黑色素瘤治疗的临床研究进展[J]. 中国癌症杂志, 2022, 32(5): 445-450.
[13]	朱逸晖, 李　婷, 胡夕春. Trastuzumab deruxtecan的临床研究进展及展望——HER2耐药患者的新希望[J]. 中国癌症杂志, 2021, 31(8): 754-761.
[14]	李　崴, 张山岭, 陶英杰, 王旭东. T细胞免疫代谢调控与免疫检查点抑制剂联合应用的现状及研究进展[J]. 中国癌症杂志, 2021, 31(7): 640-646.
[15]	王　洁. 免疫检查点抑制剂在肺癌治疗应用中的挑战与方向[J]. 中国癌症杂志, 2020, 30(10): 744-749.